{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:16:54Z","timestamp":1791911814861,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"UCB"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, showed efficacy to 2 years in patients with axial spondyloarthritis (axSpA). In this post hoc analysis, we compare the impact of shorter versus longer symptom duration on the efficacy of bimekizumab to Week 104.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Efficacy outcomes by symptom duration (\u2264\u20092 [ASAS early axSpA definition] versus &gt;\u20092 years; \u2264\u20095 versus &gt;\u20095 years) were assessed across patients from BE MOBILE 1 and 2 (non-radiographic [NCT03928704]\/radiographic axSpA [NCT03928743]) and the combined open-label extension (NCT04436640). (Relative) odds ratios and (relative) differences were calculated to compare 16-week bimekizumab versus placebo treatment effect and 104-week outcomes, and infer the significance of differences, between symptom duration subgroups. Analyses were neither powered for these comparisons nor multiplicity adjusted, and should be interpreted accordingly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Improved disease activity, physical function, fatigue, health-related quality of life and objective signs of inflammation were seen with bimekizumab versus placebo at Week 16 regardless of symptom duration. Outcomes were then sustained or improved with bimekizumab to Week 104 across all subgroups.<\/jats:p>\n                    <jats:p>16-week bimekizumab versus placebo treatment effect was comparable between subgroups (e.g., \u2264\u20092-year versus &gt;\u20092-year symptom duration relative odds ratio [95% CI] for ASDAS &lt;\u20092.1 in BE MOBILE 1: 0.82 [0.22, 3.08]). Significant differences were observed for some 104-week outcomes between symptom duration subgroups across both studies (e.g., \u2264\u20095-year versus &gt;\u20095-year symptom duration odds ratio [95% CI] for ASDAS &lt;\u20092.1 in BE MOBILE 2: 1.94 [1.02, 3.68]), all favouring the shorter symptom duration subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bimekizumab was efficacious to 2 years regardless of symptom duration, with comparable 16-week treatment effect but generally better 104-week outcomes in the shorter versus longer symptom duration subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Registered on ClinicalTrials.gov; NCT03928704 (BE MOBILE 1; 23rd April 2019), NCT03928743 (BE MOBILE 2; 23rd April 2019), NCT04436640 (BE MOVING; 15th June 2020).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-026-03729-6","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:03:26Z","timestamp":1768820606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of symptom duration on the short- and long-term efficacy of bimekizumab in axial spondyloarthritis: results up to 2 years"],"prefix":"10.1186","volume":"28","author":[{"given":"Sofia","family":"Ramiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Proft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Sengupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"van Tubergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Molt\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne S.","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsumasa","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawna","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"3729_CR1","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/RHU.0000000000000589","volume":"23","author":"V Strand","year":"2017","unstructured":"Strand V, Singh JA. Patient burden of axial spondyloarthritis. J Clin Rheumatol. 2017;23:383\u201391.","journal-title":"J Clin Rheumatol"},{"key":"3729_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","volume":"405","author":"V Navarro-Compan","year":"2025","unstructured":"Navarro-Compan V, Sepriano A, Capelusnik D, et al. Axial spondyloarthritis Lancet. 2025;405:159\u201372.","journal-title":"Axial Spondyloarthritis Lancet"},{"key":"3729_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/ard-2023-225185","volume":"83","author":"D van der Heijde","year":"2024","unstructured":"van der Heijde D, Molto A, Ramiro S, et al. Goodbye to the term \u2018ankylosing spondylitis\u2019, hello \u2018axial spondyloarthritis\u2019: time to embrace the ASAS-defined nomenclature. Ann Rheum Dis. 2024;83:547\u20139.","journal-title":"Ann Rheum Dis"},{"key":"3729_CR4","doi-asserted-by":"publisher","first-page":"e001108","DOI":"10.1136\/rmdopen-2019-001108","volume":"5","author":"C L\u00f3pez-Medina","year":"2019","unstructured":"L\u00f3pez-Medina C, Ramiro S, van der Heijde D, et al. Characteristics and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis: a comparison by systematic literature review and meta-analysis. RMD Open. 2019;5:e001108.","journal-title":"RMD Open"},{"key":"3729_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet. 2017;390:73\u201384.","journal-title":"Lancet"},{"key":"3729_CR6","doi-asserted-by":"publisher","first-page":"152032","DOI":"10.1016\/j.semarthrit.2022.152032","volume":"55","author":"D Benavent","year":"2022","unstructured":"Benavent D, Capelusnik D, van der Heijde D, et al. How is early spondyloarthritis defined in the literature? Results from a systematic review. Semin Arthritis Rheum. 2022;55:152032.","journal-title":"Semin Arthritis Rheum"},{"key":"3729_CR7","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/ard-2023-224232","volume":"83","author":"V Navarro-Comp\u00e1n","year":"2024","unstructured":"Navarro-Comp\u00e1n V, Benavent D, Capelusnik D, et al. ASAS consensus definition of early axial spondyloarthritis. Ann Rheum Dis. 2024;83:1093\u20139.","journal-title":"Ann Rheum Dis"},{"key":"3729_CR8","doi-asserted-by":"publisher","first-page":"102307","DOI":"10.1016\/j.coph.2022.102307","volume":"67","author":"R Sen","year":"2022","unstructured":"Sen R, Caplan L. Current treatment and molecular targets for axial spondyloarthritis: Evidence from randomized controlled trials. Curr Opin Pharmacol. 2022;67:102307.","journal-title":"Curr Opin Pharmacol"},{"key":"3729_CR9","doi-asserted-by":"publisher","first-page":"105603","DOI":"10.1016\/j.jbspin.2023.105603","volume":"90","author":"D Benavent","year":"2023","unstructured":"Benavent D, Capelusnik D, Ramiro S, et al. Looking through the window of opportunity in axial spondyloarthritis? Joint Bone Spine. 2023;90:105603.","journal-title":"Joint Bone Spine"},{"key":"3729_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"R Adams","year":"2020","unstructured":"Adams R, Maroof A, Baker T, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894.","journal-title":"Front Immunol"},{"key":"3729_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77:523\u201332.","journal-title":"Ann Rheum Dis"},{"key":"3729_CR12","doi-asserted-by":"publisher","first-page":"e001306","DOI":"10.1136\/rmdopen-2020-001306","volume":"6","author":"M Shah","year":"2020","unstructured":"Shah M, Maroof A, Gikas P, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020;6:e001306.","journal-title":"RMD Open"},{"key":"3729_CR13","unstructured":"European Medicines Agency (EMA). Bimekizumab summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bimzelx-epar-productinformation_en.pdf.\u00a0Accessed 1 July 2025."},{"key":"3729_CR14","unstructured":"Food and Drug Administration (FDA). Bimzelx\u00ae US prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761151s000lbl.pdf.\u00a0Accessed 1 July 2025."},{"key":"3729_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/ard-2022-223595","volume":"82","author":"D van der Heijde","year":"2023","unstructured":"van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023;82:515\u201326.","journal-title":"Ann Rheum Dis"},{"key":"3729_CR16","doi-asserted-by":"publisher","first-page":"e005081","DOI":"10.1136\/rmdopen-2024-005081","volume":"11","author":"A Deodhar","year":"2025","unstructured":"Deodhar A, Navarro-Comp\u00e1n V, Poddubnyy D, et al. Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension. RMD Open. 2025;11:e005081.","journal-title":"RMD Open"},{"key":"3729_CR17","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1093\/rheumatology\/keaf009","volume":"64","author":"X Baraliakos","year":"2025","unstructured":"Baraliakos X, Deodhar A, van der Heijde D, et al. Long-Term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-Year results from two phase 3 studies. Rheumatology. 2025;64:3534\u201346.","journal-title":"Rheumatology"},{"key":"3729_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/ard-2023-224803","volume":"83","author":"X Baraliakos","year":"2024","unstructured":"Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024;83:199\u2013213.","journal-title":"Ann Rheum Dis"},{"key":"3729_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.62.1.20","volume":"62","author":"LC Doward","year":"2003","unstructured":"Doward LC, Spoorenberg A, Cook SA, et al. Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis. 2003;62:20\u20136.","journal-title":"Ann Rheum Dis"},{"key":"3729_CR20","doi-asserted-by":"crossref","unstructured":"Ciurea A, G\u00f6tschi A, Br\u00e4m R, et al. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry. RMD Open. 2023;9:e003455.","DOI":"10.1136\/rmdopen-2023-003455"},{"key":"3729_CR21","doi-asserted-by":"publisher","first-page":"e005110","DOI":"10.1136\/rmdopen-2024-005110","volume":"11","author":"V Navarro-Comp\u00e1n","year":"2025","unstructured":"Navarro-Comp\u00e1n V, Van den Bosch F, Sampaio-Barros PD, et al. Efficacy of upadacitinib in subgroups of patients with axial spondyloarthritis with early versus established disease. RMD Open. 2025;11:e005110.","journal-title":"RMD Open"},{"key":"3729_CR22","doi-asserted-by":"crossref","unstructured":"Benavent D, Navarro-Comp\u00e1n V, Capelusnik D, et al. Does symptom duration impact on treatment response in axial spondyloarthritis? A meta-analysis of randomized controlled trials. Rheumatology. 2025:64:5872\u201382.","DOI":"10.1093\/rheumatology\/keaf382"},{"key":"3729_CR23","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/rheumatology\/keac532","volume":"62","author":"D Capelusnik","year":"2022","unstructured":"Capelusnik D, Benavent D, van der Heijde D, et al. Treating spondyloarthritis early: does it matter? Results from a systematic literature review. Rheumatology. 2022;62:1398\u2013409.","journal-title":"Rheumatology"},{"key":"3729_CR24","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1136\/annrheumdis-2019-eular.2829","volume":"78","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Boonen A, Ferraccioli G, et al. Fri0388\u2005secukinumab improves health-related quality of life in patients with ankylosing spondylitis, irrespective of time since first diagnosis pooled results from the secukinumab phase 3 trial program. Ann Rheum Dis. 2019;78:878.","journal-title":"Ann Rheum Dis"},{"key":"3729_CR25","unstructured":"Navarro-Comp\u00e1n V, Maldonado-Cocco J, Rahman P, et al. Response to treatment with ixekizumab in patients with active non-radiographic axial spondyloarthritis based on HLA-B27 status and disease duration [abstract]. Arthritis Rheumatol. 2020;72(suppl 10)."},{"key":"3729_CR26","unstructured":"Deodhar A, Mease P, Machado P, et al. Impact of age and disease duration on the response to IL-17A inhibitor (secukinumab) treatment in ankylosing spondylitis: Pooled results from the phase 3 MEASURE studies [abstract]. Arthritis Rheumatol. 2019;71(suppl 10)."},{"key":"3729_CR27","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/rheumatology\/keh199","volume":"43","author":"VPK Nell","year":"2004","unstructured":"Nell VPK, Machold KP, Eberl G, et al. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology. 2004;43:906\u201314.","journal-title":"Rheumatology"},{"key":"3729_CR28","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1093\/rheumatology\/keae212","volume":"64","author":"SL Heckert","year":"2025","unstructured":"Heckert SL, Maassen JM, Nevins I, et al. Long-term clinical outcomes in early rheumatoid arthritis that was treated-to-target in the BeST and IMPROVED studies. Rheumatology. 2025;64:1052\u20139.","journal-title":"Rheumatology"},{"key":"3729_CR29","unstructured":"Ramiro S, Proft F, Sengupta R, et al. Bimekizumab treatment was efficacious to 2 years regardless of duration of axSpA symptoms: Results from two phase 3 studies [abstract]. Arthritis Rheumatol. 2024;76(suppl 9)."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-026-03729-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03729-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-026-03729-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:49:56Z","timestamp":1781632196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-026-03729-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3729"],"URL":"https:\/\/doi.org\/10.1186\/s13075-026-03729-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BE MOBILE 1, BE MOBILE 2 and BE MOVING studies were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Guidance for Good Clinical Practice. Ethical approvals were obtained from the relevant institutional review boards at participating sites. All patients provided written informed consent in accordance with local requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SR: Consultant for AbbVie, Alfasigma, Eli Lilly, Johnson & Johnson, MSD, Novartis, Pfizer, Sanofi and UCB; grants from AbbVie, Alfasigma, MSD, Novartis, Pfizer and UCB; FP: Grant\/research support from Eli Lilly and Company, Novartis and UCB; consultancy fees and speakers\u2019 bureau from AbbVie, Amgen, BMS, Celgene, Eli Lilly and Company, Galapagos, Hexal, Janssen, Medscape, MoonLake Pharma, MSD, Novartis, Pfizer, Roche and UCB; RS: Speaker for AbbVie, Biogen, Celgene, MSD, Novartis and UCB; consultant for AbbVie, Biogen, Celgene, Eli Lilly, MSD, Novartis and UCB; research grants from AbbVie, Celgene and UCB; AvT: Speaker for Pfizer and Novartis; consultant for Novartis, Johnson and Johnson, Pfizer and UCB; grant\/research support from MSD, Novartis, Pfizer and UCB; AM: Consultant for AbbVie, MSD, Pfizer and UCB; grant\/research support from AbbVie, MSD, Pfizer and UCB; LSG: Grants from UCB paid to institution; consulting fees from Acelyrin, Eli Lilly, Janssen, Novartis, Pfizer and UCB; MK: Speakers\u2019 bureau for AbbVie, Amgen, Asahi-Kasei Pharma, Ayumi Pharma, BMS, Chugai, Daiichi Sankyo, Eisai, Gilead, Janssen, Lilly, Novartis, Tanabe-Mitsubishi and UCB; consultant for AbbVie, Amgen, Asahi-Kasei Pharma, Ayumi Pharma, BMS, Chugai, Gilead, Janssen, Lilly, Novartis, Takeda, Tanabe-Mitsubishi and UCB; VT: Employee and shareholder of UCB; SK: Consultant for Aclipse Therapeutics, Aliada Therapeutics, Allay Therapeutics, Autobahn Therapeutics, Cognition Therapeutics, Colorado Prevention Center, Karuna Therapeutics, Kisbee Therapeutics, LB Pharmaceuticals, Nesos, Novartis, Onward Medical, PharPoint Research, Summit Analytical, Therini Bio, Tonix Pharmaceuticals, Tornado Therapeutics, UCB, Whitsell Innovations, Worldwide Clinical Trials and Zosano Pharma; SE: Employee of UCB; VNC: Speaker for AbbVie, Eli Lilly and Company, Fresenius Kabi, Janssen, MSD, Novartis, Pfizer and UCB; consultant for AbbVie, Alfasigma, Eli Lilly and Company, Galapagos, MoonLake, MSD, Novartis, Pfizer and UCB; grant\/research support from AbbVie and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}